1,410
Views
0
CrossRef citations to date
0
Altmetric
Case Report

AL type cardiac amyloidosis: a devastating fatal disease

, , , , &
Pages 407-412 | Received 02 Feb 2021, Accepted 07 Apr 2021, Published online: 10 May 2021

References

  • Xu ZW, Li YQ, Liu LX, et al. Light-chain cardiac amyloidosis with neuropathy: a case report. Clin Interv Aging. 2015;10:1219–1222.
  • Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–540.
  • Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18(Suppl 2):s30–s5.
  • Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364.
  • Giorgetti A, Genovesi D, Milan E, et al. Cardiac amyloidosis. Clin Transl Imaging. 2019;7(1):21–32.
  • Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018;43(1):10–34.
  • Meng L, Wh D, Lb S, et al. [The clinical features and outcomes of immunoglobulin light-chain amyloidosis with heart involvement]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35(4):340–343.
  • Cheng Z, Zhu K, Tian Z, et al. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013;18(4):157–162.
  • Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59(5):418–422.
  • Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22.
  • Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–1933.
  • Hassan W, Al-Sergani H, Mourad W, et al. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32(2):178–184.
  • Giancaterino S, Urey MA, Darden D, et al. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(2):351–361.
  • Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207.
  • Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93(3):1062–1066.
  • Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–3430.
  • Karamitsos TD, Neubauer S. T1 mapping and amyloid cardiomyopathy: how much better can it get?. Eur Heart J. 2014;36(4):203–205.
  • Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–995.